NovoCure (NVCR) Current Assets (2014 - 2026)

NovoCure (NVCR) has reported Current Assets for 13 consecutive years, with $638.5 million the latest figure, recorded in Q2 2026.

• Quarterly Current Assets fell 41.06% year-over-year to $638.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $638.5 million (down 41.06% YoY) and the FY2025 annual result came in at $646.7 million, down 41.56% from the prior year.
• Current Assets improved to $638.5 million in Q2 2026 per NVCR's latest filing, from $631.7 million in the prior quarter.
• Over the last five years, Current Assets for NVCR reached as high as $1.2 billion in Q3 2025 and fell as low as $631.7 million in Q1 2026.
• A 5-year average of $1.0 billion and a median of $1.1 billion in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2025 — Current Assets climbed 9.55% — and 2026, when it tumbled 42.01%.
• Year by year, Current Assets stood at $1.1 billion in 2022, then decreased by 6.94% to $1.0 billion in 2023, then increased by 6.98% to $1.1 billion in 2024, then slumped by 41.56% to $646.7 million in 2025, then fell by 1.27% to $638.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $638.5 million, $631.7 million, and $646.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.